ANG1005  (Synonyms: GRN1005; Paclitaxel trevatide)

ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system^[1][2][3].

ANG1005 shows significantly improved delivery to brain and brain metastases of breast cancer compared to free paclitaxel (HY-B0015)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5109.36

C₂₅₇H₃₀₈N₃₂O₇₉

1075214-55-9

Solid

White to off-white

{Paclitaxel-Thr}-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-{Paclitaxel-Lys}-Arg-Asn-Asn-Phe-{Paclitaxel-Lys}-Thr-Glu-Glu-Tyr

{Paclitaxel-T}FFYGGSRG{Paclitaxel-K}RNNF{Paclitaxel-K}TEEY

Shipping with dry ice.

-80°C

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months. When stored at -80°C, please use it within 6 months.

• [1]. Thomas FC, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res. 2009 Nov;26(11):2486-94.  [Content Brief]

  [2]. Li F, et al. Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB). Genes Dis. 2017 Feb 10;4(1):1-3.  [Content Brief]

  [3]. Kumthekar P, et al. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020 Jun 15;26(12):2789-2799.  [Content Brief]